The agency reported actions against a biotech company and two large stem cell clinics over unapproved treatments, a move it said was necessary to make way for speedier approval of legitimate therapies.
Published: August 28, 2017 at 02:00AM
from NYT Health https://ift.tt/2wj2NtQ